Unknown

Dataset Information

0

Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases.


ABSTRACT: To investigate the effects of immunoembolization with granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with uveal melanoma (UM) with liver-only metastasis.In this double-blind phase II clinical trial, patients were randomized to undergo immunoembolization or bland embolization (BE). Lobar treatment was performed with GM-CSF or normal saline solution mixed with ethiodized oil followed by embolization with gelatin sponge emulsified with iodinated contrast medium. Fifty-two patients (immunoembolization, n = 25; BE, n = 27) were enrolled. Response was assessed after every two treatments. The primary endpoint was overall response rate (ORR) of liver metastases. Progression-free survival (PFS), overall survival (OS), and immunologic responses were secondary endpoints.There were five partial responses in the immunoembolization group (ORR, 21.2%; 90% confidence interval [CI], 10.3%-30.5%) and three in the BE group (ORR, 16.7%; 90% CI, 6.3%-26.9%). Stable disease was seen in 12 patients in the immunoembolization group and 19 in the BE group. OS times were 21.5 months (95% CI, 18.5-24.8 mo) with immunoembolization and 17.2 months (95% CI, 11.9-22.4 mo) with BE. The degree of proinflammatory cytokine production was more robust after immunoembolization and correlated with time to "systemic" extrahepatic progression. In the immunoembolization group, interleukin (IL)-6 levels at 1 hour (P = .001) and IL-8 levels at 18 hours after the procedure (P < .001) were significant predictors of longer systemic PFS. Moreover, a dose-response pattern was evident between posttreatment serum cytokine concentrations and systemic PFS.Immunoembolization induced more robust inflammatory responses, which correlated with the delayed progression of extrahepatic systemic metastases.

SUBMITTER: Valsecchi ME 

PROVIDER: S-EPMC4417549 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases.

Valsecchi Matias E ME   Terai Mizue M   Eschelman David J DJ   Gonsalves Carin F CF   Chervoneva Inna I   Shields Jerry A JA   Shields Carol L CL   Yamamoto Akira A   Sullivan Kevin L KL   Laudadio MaryAnn M   Berd David D   Mastrangelo Michael J MJ   Sato Takami T  

Journal of vascular and interventional radiology : JVIR 20150209 4


<h4>Purpose</h4>To investigate the effects of immunoembolization with granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with uveal melanoma (UM) with liver-only metastasis.<h4>Materials and methods</h4>In this double-blind phase II clinical trial, patients were randomized to undergo immunoembolization or bland embolization (BE). Lobar treatment was performed with GM-CSF or normal saline solution mixed with ethiodized oil followed by embolization with gelatin sponge emulsified  ...[more]

Similar Datasets

| S-EPMC4995227 | biostudies-literature
| S-EPMC2920049 | biostudies-literature
| S-EPMC10127946 | biostudies-literature
| S-EPMC5916331 | biostudies-literature
| S-EPMC3852053 | biostudies-literature
| S-EPMC3707315 | biostudies-literature
| S-EPMC5926922 | biostudies-literature
| S-EPMC404575 | biostudies-literature
| S-EPMC3014056 | biostudies-literature